Difference between revisions of "Abemaciclib (Verzenio)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Kinase inhibitors" to "") |
m |
||
| Line 12: | Line 12: | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' LY2835219 | *'''Code name:''' LY2835219 | ||
| − | *'''Brand name:''' Verzenio | + | *'''Brand name:''' Verzenio, Verzenios |
[[Category:Drugs]] | [[Category:Drugs]] | ||
| Line 18: | Line 18: | ||
[[Category:Protein expression-specific medications]] | [[Category:Protein expression-specific medications]] | ||
| − | + | [[Category:CDK4 inhibitors]] | |
| − | [[Category: | + | [[Category:CDK6 inhibitors]] |
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] | ||
[[Category:FDA approved in 2017]] | [[Category:FDA approved in 2017]] | ||
Revision as of 15:34, 4 January 2021
Mechanism of action
From NCI Drug Dictionary: An orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. Abemaciclib specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation in early G1.
Diseases for which it is used
History of changes in FDA indication
- 9/28/2017: FDA approved in combination with fulvestrant for women with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.
- 9/28/2017: FDA approved as monotherapy for women and men with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.
- 2/26/2018: FDA approved in combination with an aromatase inhibitor as initial endocrine-based therapy for postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Also known as
- Code name: LY2835219
- Brand name: Verzenio, Verzenios